Clinical Trial Update: A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab [Phase 2]

View source ↗

Summary

A multicenter Phase 2, single-arm proof-of-concept trial is evaluating obinutuzumab for non-infectious active cryoglobulinemic vasculitis in patients refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryoglobulinemic Vasculitis

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Cryoglobulinemic Vasculitis (CV) | Phase 2 | Status: NOT_YET_RECRUITING